Anthrax grant award - 4 Feb 2014
From the Hawaii Biotech archive: (HONOLULU, HI, Feb. 4, 2014) - The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc., a grant to continue the development of anthrax an
HBI Awarded Subcontract by Leidos for Biodefense Work
From the Hawaii Biotech archive: (RESTON, VA, and HONOLULU, HI, Nov. 4, 2013) - Leidos (NYSE: LDOS), a national security, health and engineering solutions company, announced it has been awarded a prime vaccine adjuvant development contract by the National Institu
Hawaii Biotech Gains Rights to West Nile Vaccine Technology from Merck
From the Hawaii Biotech archive: (HONOLULU, April 11, 2013) - Hawaii Biotech, Inc., (HBI), a Hawaii-based biotech company focused on the development of recombinant protein subunit vaccines for infectious disease, announced today that it has acquired ownership of
Hawaii Biotech Receives Crimean-Congo Hemorrhagic Fever Vaccine Grant
From the Hawaii Biotech archive: (HONOLULU, June 28, 2012) -- Hawaii Biotech, Inc. was awarded a two-year SBIR phase I grant from the National Institute of Allergy and Infectious Disease to continue development of a vaccine to protect healthy individuals against
Hawaii Biotech Licenses Vaccine Technology from Merck
From the Hawaii Biotech archive: (HONOLULU, November 1, 2011) - Hawaii Biotech, Inc., (HBI), a Hawaii-based biotech company focused on the development of recombinant protein subunit vaccines for infectious disease, announced today that it has acquired an exclusiv
Hawaii Biotech Exits Bankruptcy
From the Hawaii Biotech archive: (HONOLULU, June 20, 2011) - Hawaii Biotech, Inc., (HBI), a Hawaii-founded biotech company focused on the development of recombinant protein subunit vaccines for infectious disease, announced today that Judge Robert Faris, presidin
Hawaii Biotech Discusses Dengue Vaccine Development at Brazil Symposium
From the Hawaii Biotech archive: (Honolulu, March 26, 2010) - Hawaii Biotech, Inc., was one of seven Dengue vaccine developers asked to speak at a recent symposium in Brazil. Beth-Ann Coller, Ph.D., senior vice president for Research and Development at Hawaii Bio
Hawaii Biotech Completes Dosing of Phase 1 Trial for Dengue Virus Monovalent Vaccine
From the Hawaii Biotech archive: (HONOLULU, Jan. 7, 2010) -- Hawaii Biotech, Inc. announced today that it has completed recruitment and dosing in a multiple dose Phase 1 clinical study of its dengue virus monovalent vaccine. The double-blind, placebo controlled,
Advanced Bioscience Laboratories to Manufacture Hawaii Biotech's Dengue Vaccine for Clinical Trials
From the Hawaii Biotech archive: (Honolulu, HI and Kensington, MD, May 25, 2010) - Hawaii Biotech, Inc. and Advanced BioScience Laboratories, Inc. (ABL) announced today they are partnering for preclinical development of a dengue vaccine. Hawaii Biotech plans to b
Hawaii Biotech Initiates Phase 1 Clinical Trial for Dengue Vaccine
From the Hawaii Biotech archive: (HONOLULU, August 25, 2009) -- Hawaii Biotech, Inc. President and CEO Elliot Parks, Ph.D., announced today that the company has initiated a Phase 1 clinical study with their monovalent dengue vaccine candidate. The double-blind, p
